StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report report published on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 0.3 %
Shares of Titan Pharmaceuticals stock opened at $4.00 on Friday. Titan Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $14.80. The firm’s 50 day moving average is $5.19 and its two-hundred day moving average is $5.91.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Consumer Staples Stocks, Explained
- From PACs to Portfolios: Billionaire Bets and Investor Reactions
- Where Do I Find 52-Week Highs and Lows?
- AppLovin Stock Quadruples: What’s Behind the Bullish Sentiment?
- Learn Technical Analysis Skills to Master the Stock Market
- Battle of the Retailers: Who Comes Out on Top?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
